Cost Analysis Of Treatment Success To Achieve A Clinically Relevant Composite Endpoint For Patients With Type-2 Diabetes On Liraglutide Or Other Antidiabetic Therapies In A Chinese Setting
Abstract
Authors
L.W. Shi S. HAN U.J. Ploug F. LIU